Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Dezember 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

HOUSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the...
13. November 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

HOUSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its...
28. Oktober 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

HOUSTON, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has...
14. Oktober 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

HOUSTON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its...
08. Oktober 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

HOUSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial...
24. September 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials

HOUSTON, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the...
13. September 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Announces Senior Leadership Changes

HOUSTON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment...
12. September 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

HOUSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for...
26. August 2019 07:00 ET | Quelle: Salarius Pharmaceuticals

Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma

PHOENIX and HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a...
12. August 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

HOUSTON, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief...

Vorherige Seite

Nächste Seite